RNA: new CGT workstream to focus on this industry priority
When planning the 2021 BioPhorum Cell & Gene Therapy program, senior member representatives indicated that they wanted a new workstream focusing on what they considered to be the most critical topic: RNA.
By early February 2021, companies were recruited to a pathfinder activity to determine what should be covered in the workstream: RNA – mRNA therapeutics and RNA tool. Discussions led to the creation of a charter, which has been reviewed by the new RNA workstream governance group consisting of 44 members from 20 companies.
From the initial 16 topics identified, four have been confirmed for further scoping by dedicated sub-teams:
- RNA-specific CQA & CPP and links to clinical performance
- Scale up challenges for RNA DS manufacturing and RNA DP
- RNA-specific assays and analytical tools/equipment
- CDMOs & CROs supporting RNA activity
In addition to establishing this new workstream, BioPhorum has been working with members to produce an article on the importance of RNA within the biomanufacturing sector, containing more information about the pathfinder and its goals. The article will be published on BioPhorum.com before the end of the year.
Cell and gene therapies (CGTs) have enormous potential to create personalized therapeutics for patients with diseases...